the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
October 08, 2010 – Today, we learn that Abbott Laboratories and FDA notified healthcare professionals and patients about the voluntary market withdrawal of Sibutramine [Meridia], an obesity drug, from the U.S. market because of clinical trial data indicating an increased …
Sibutramine [Meridia]: Market Withdrawal Due to Risk of Serious Cardiovascular events Read more »
July 11, 2010 – Do the people behind such products at all know what they do? On July 08, 2010, the FDA has issued the following warning concerning the Que She Herbal Supplement and its Undeclared Drug Ingredients: AUDIENCE: Consumer, …
April 11, 2010 – FDA is alerting healthcare professionals that Sibutramine [Meridia] is contraindicated in patients with a history of cardiovascular disease because the drug increases their risk of heart attack and stroke. Sibutramine [Meridia] is used to manage obesity. …